Lg Chem, Ltd

Ohhwan Kwon

Hwan Geun Choi

So Young Kim

Jung Beom Son

Young Kwan Kim

Yi Kyung Ko

Seungyeon Lee

Seock Yong Kang

Eunhwa Ko

Jin-Hee Park

Heedong Park

Junggyu Park

The present invention relates to a novel compound exhibiting enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing and treating metabolic diseases such as obesity, diabetes mellitus or hyperlipidemia, etc. comprising the compound or pharmaceutically acceptable salt, and a method for preventing or treating metabolic disease using the above novel compound. The compound of the present invention has excellent inhibitory activity against enteropeptidase, and thus is not absorbed into the body, but are excreted outside the body. However, since not only fat but also protein are discharged together, it has few side effects such as fat stools and acts only in the gastrointestinal tract, so it has few side effects such as depression, and is very useful as a therapeutic or prophylactic drug for various metabolic diseases such as obesity, diabetes mellitus, and hyperlipidemia.

Compound exhibiting enteropeptidase inhibitory activity

Growing community of inventors

Daejeon, South Korea

Ohhwan Kwon